LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Akciju saraksts・Simulations Plus Inc

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

15.77 -4.83

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

15.7

Max

16.61

Galvenie mērījumi
By Trading Economics
Ienākumi	3.9M 4.5M
Pārdošana	5.9M 24M
EPS	0.35
Peļņas marža	18.669
Darbinieki	212
EBITDA	4.9M 7.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-3.9% downside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 13. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	107M 358M
Iepriekšējā atvēršanas cena	20.6
Iepriekšējā slēgšanas cena	15.77

Ziņu noskaņojums

By Acuity

50%

155 / 344 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. jūn. 19:20 UTC

Galvenie tirgus virzītāji

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

2026. g. 5. jūn. 21:27 UTC

Peļņas

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

2026. g. 5. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. jūn. 20:20 UTC

Iegādes, apvienošanās, pārņemšana

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

2026. g. 5. jūn. 20:19 UTC

Iegādes, apvienošanās, pārņemšana

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

2026. g. 5. jūn. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 5. jūn. 19:26 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 5. jūn. 19:26 UTC

Tirgus saruna

Hog Futures Tumble to Close Week -- Market Talk

2026. g. 5. jūn. 19:10 UTC

Tirgus saruna

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

2026. g. 5. jūn. 19:03 UTC

Tirgus saruna

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

2026. g. 5. jūn. 18:59 UTC

Tirgus saruna

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

2026. g. 5. jūn. 18:47 UTC

Tirgus saruna

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

2026. g. 5. jūn. 18:34 UTC

Tirgus saruna

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

2026. g. 5. jūn. 18:33 UTC

Iegādes, apvienošanās, pārņemšana

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

2026. g. 5. jūn. 17:50 UTC

Peļņas

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

2026. g. 5. jūn. 17:27 UTC

Tirgus saruna

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

2026. g. 5. jūn. 16:48 UTC

Iegādes, apvienošanās, pārņemšana

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 5. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 5. jūn. 15:44 UTC

Iegādes, apvienošanās, pārņemšana

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026. g. 5. jūn. 15:26 UTC

Tirgus saruna

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

2026. g. 5. jūn. 15:25 UTC

Peļņas

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

2026. g. 5. jūn. 15:16 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 5. jūn. 15:16 UTC

Tirgus saruna

Zcash Tumbles After Exploit Found -- Market Talk

2026. g. 5. jūn. 15:09 UTC

Tirgus saruna

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

2026. g. 5. jūn. 15:07 UTC

Tirgus saruna

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

2026. g. 5. jūn. 15:05 UTC

Tirgus saruna

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-3.9% uz leju

Prognoze 12 mēnešiem

Vidējais 16 USD -3.9%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

155 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.